DarioHealth ( DRIO ) shares were up 9% on Monday after the company said it has received approval from Australia's Therapeutic Goods Administration for its Lightning-enabled version of the Blood Glucose Monitoring System.
With the approval, Dario said consumers in the Australian market will be able to receive the same user experience with DarioHealth on the latest Apple ( AAPL ) devices, including the iPhone 8 and iPhone X.
In addition to the TGA approval, users in the UK will be able to purchase the Lightning-enabled Dario device at the end of this month while sales of the device will begin in Australia by January. DarioHealth is still waiting on approval from regulatory agencies in the US and Canada, which is expected in the coming months.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
